1118567-11-5Relevant articles and documents
Development of Novel 18F-PET Agents for Tumor Hypoxia Imaging
Wang, Li,Wang, Hui,Shen, Kun,Park, Hyejin,Zhang, Tao,Wu, Xuedan,Hu, Mei,Yuan, Hong,Chen, Yue,Wu, Zhanhong,Wang, Qiu,Li, Zibo
, p. 5593 - 5602 (2021)
Tumor hypoxia is a major factor responsible for tumor progression, metastasis, invasion, and treatment resistance, leading to low local tumor control and recurrence after radiotherapy in cancers. Here,18F-positron emission tomography (PET) probes are developed for visualizing viable hypoxic cells in biopsies. Pimonidazole derivatives and nitroimidazole-based agents bearing sulfonyl linkers were evaluated. A small-animal PET study showed that the tumor uptake of [18F]-23 [poly(ethylene glycols) (PEG)-sulfonyl linker] of 3.36 ± 0.29%ID/g was significantly higher (P 0.01) than that of [18F]-20 (piperazine-linker tracer, 2.55 ± 0.49%ID/g) at 2 h postinjection in UPPL tumors. The tumor-to-muscle uptake ratio of [18F]-23 (2.46 ± 0.48 at 2 h pi) was well improved compared with that of [18F]-FMISO (1.25 ± 0.14 at 2 h pi). A comparable distribution pattern was observed between ex vivo autoradiography of [18F]-23 and pimonidazole staining of the neighboring slice, indicating that [18F]-23 is a promising PET agent for hypoxia imaging.
RADIOLABELED COMPOUNDS
-
Page/Page column 84; 85, (2019/07/13)
The present invention relates to radiolabeled compounds of formula (I) wherein either A, B, R1, R2, is labeled with a radionuclide selected from 3H, 11C and 18F and its use for imaging alpha synuclein and/or Abeta deposits in mammals.
COMPOUNDS FOR USING IN IMAGING AND PARTICULARLY FOR THE DIAGNOSIS OF NEURODEGENERATIVE DISEASES
-
Paragraph 0820; 0821, (2019/07/23)
The invention relates to compounds of formula (II) for using in imaging and particularly for the diagnosis of neurodegenerative diseases
